

11/21/01

11-23-01

PTO/SB/05 (3-01)  
OMB 0651-0032

Approved for use through 09/30/2000.

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Please type a plus sign (+) inside this box → ☐

# UTILITY PATENT APPLICATION TRANSMITTAL

Attorney Docket No. PC11050A

First Inventor Xuemei Cao

Title ATTENUATED FORMS OF BOVINE VIRAL DIARRHEA VIRUS

Express Mail Label No. EL 768261649 US

(Only for new nonapplications under 37C.F.R. §1.53(b))

## APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

ADDRESS TO:

Commissioner for Patents  
Box Patent Application  
Washington, DC 20231

1. ☒ \*Fee Transmittal Form (e.g., PTO/SB/17)  
(Submit an original, and a duplicate for fee processing)
2. ☐ Applicant claims small entity status  
See 37 CFR 1.27
3. ☒ Specification [Total Pages 28]  
(preferred arrangement set forth below)
- Descriptive title of the Invention
  - Cross References to Related Applications
  - Statement Regarding Fed sponsored R&D
  - Reference to sequence listing, a table, or a computer program listing appendix
  - Background of the Invention
  - Brief Summary of the Invention
  - Brief Description of the Drawings (if filed)
  - Detailed Description
  - Claim(s)
  - Abstract of the Disclosure
4. ☒ Drawing(s) (35 U.S.C. 113) [Total sheets 13]
5. ☒ Oath or Declaration [Total pages 3]
- a. ☒ Newly executed (original or copy)
- b. ☐ Copy from a prior application (37 CFR §1.53(d))  
(for continuation/divisional with Box 18 completed)
- i. ☐ **DELETION OF INVENTOR(S)**  
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).
6. ☒ Application Data Sheet. See 37 CFR 1.76
7. ☐ CD-ROM or CD-R in duplicate, large table or computer Program (Appendix)
8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
- a. ☒ Computer Readable Copy (CRF)
- b. Specification Sequence Listing on:
- i. ☐ CD-ROM or CD-R (2 copies)
- ii. ☒ Paper
- c. ☒ Statement verifying identity of above copies

## ACCOMPANYING APPLICATION PARTS

9. ☐ Assignment Papers (cover sheet & document(s))
10. ☐ 37 CFR 3.73(b) Statement ☐ Power of Attorney  
(when there is an assignee)
11. ☐ English Translation Document (if applicable)
12. ☐ Information Disclosure Statement (IDS)/PTO-1449 ☐ Copies of IDS Citations
13. ☐ Preliminary Amendment
14. ☒ Return Receipt Postcard (MPEP 503)  
(Should be specifically itemized)
15. ☐ Certified Copy of Priority Document(s)  
(if foreign priority is claimed)
16. ☐ Nonpublication Request under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent.
17. ☐ Other:

18. If a **CONTINUING APPLICATION**, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37CFR 1.76.

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No: /

Prior application information: Examiner \_\_\_\_\_ Group/Art Unit: \_\_\_\_\_

For **CONTINUATION OR DIVISIONAL APPS** only. The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts

## 18. CORRESPONDENCE ADDRESS

☒ Customer Number or Bar Code Label (Insert Customer No. or Attach bar code label here) or ☐ Correspondence address below




23913

Name			
Address			
City	State	Zip Code	
Country	Telephone	Fax	

NAME (Print/type)	Lorraine B. Ling	Registration No. (Attorney/Agent)	35,251
Signature	<i>Xuemei Cao</i>	Date	November 21, 2001

11/21/01



11031 U.S. PTO

Approved for use through 10/31/2002. OMB 0551-0052  
 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
 Under the Paperwork reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# **FEE TRANSMITTAL** **For FY 2001**

*Patent Fees are subject to annual Revision*

Total Amount of Payment (\$) 2778 00

## **Complete if Known**

Application Number	Not Yet Assigned
Filing Date	November 21, 2001
First Named Inventor	Xuemei Cao
Examiner Name	Not Yet Assigned
Group/Art Unit	Not Yet Assigned
Attorney Docket No.	PC11050A

## **METHOD OF PAYMENT**

1. ☒ The commissioner is hereby authorized to charge indicated fees and credit any over payments to:

16-1445

Pfizer Inc

☒ Charge Any Additional Fee Required Under 37 CFR 1.16 and 1.17

☐ Applicant claims small entity status. See 37 CFR 1.27

## **2. Payment Enclosed:**

☐ Check ☐ Credit card ☐ Money Order ☐ Other

## **FEE CALCULATION**

### **1. BASIC FILING FEE**

Large Entity Fee Code	Large Entity Fee (\$)	Small Entity Fee Code	Small Entity Fee (\$)	Fee Description	Fee Paid
101	740	201	355	Utility filing fee	740
102	330	206	165	Design filing fee	
103	510	207	255	Plant filing fee	
104	740	208	370	Reissue filing fee	
111	160	214	80	filing fee	
SUBTOTAL (1) (\$)					740

### **2. EXTRA CLAIM FEES**

			Extra Claims	Fee from below	Fee Paid
Total Claims	29	-20**=	9	X 18	= 162
Independent Claims	22	-3**=	19	X 84	= 1596
Multiple Dependent					= 280
Large Entity Fee Code	Large Entity Fee	Small Entity Fee Code	Small Entity Fee	Fee Description	
103	18	203	9	Claims in excess of 20	
102	84	202	42	Independent claims in excess of 3	
104	280	204	140	Multiple dependent claim, if not paid	
109	80	209	42	**Reissue independent claims over original patent	
110	18	210	9	**Reissue claims in excess of 20 and over original patent	
SUBTOTAL (2) (\$)					2038

\*\* or number previously paid, if greater; For Reissues, see above

### **3. ADDITIONAL FEES**

Fee Code	Large Entity Fee (\$)	Fee Code	Small Entity Fee (\$)	Fee Description	Fee Paid
105	130	205	65	Surcharge - late fee or oath	
127	50	227	25	Surcharge-late filing fee or cover sheet	
139	130	139	130	Non-English specification	
147	2,520	147	2,520	For filing a request for <i>ex parte</i> reexamination	
112	920*	112	920*	Requesting publication of SIR prior to Examiner action	
113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action	
115	110	215	55	Extension for reply within first month	
116	400	216	200	Extension for reply within second month	
117	920	217	460	Extension for reply within third month	
118	1,440	218	720	Extension for reply within fourth month	
128	1,960	228	980	Extension for reply within fifth month	
119	320	219	160	Notice of Appeal	
120	320	220	160	Filing a brief in support of an appeal	
121	280	221	140	Request for oral hearing	
138	1,510	138	1,510	Petition to institute a public use proceeding	
140	110	240	55	Petition to revive - unavoidable	
141	1,280	241	640	Petition to revive - unintentional	
142	1,280	242	640	Utility issue fee (or reissue)	
143	460	243	230	Design issue fee	
144	620	244	310	Plant issue fee	
122	130	122	130	Petitions to the Commissioner	
123	50	123	50	Processing fee under 37 CFR 1.17(a)	
126	180	126	180	Submission of Information Disclosure Stmt	
581	40	581	40	Recording each patent assignment per property (times number of properties)	
146	740	246	370	Filing a submission after final rejection (37 CFR 1.129(a))	
149	740	249	370	For each additional invention to be examined (37 CFR § 1.129(b))	
179	710	279	355	Request for Continued Examination(RCE)	
169	900	169	900	Request for expedited examination of a design application	
Other (specify)					
*Reduced by Basic Filing Fee Paid					
SUBTOTAL (3)					

## **SUBMITTED BY**

## **Complete (if applicable)**

Type or Printed Name	Lorraine B. Ling	Registration No (Attorney/Agent)	35,251	Telephone	212-573-2030
Signature	<i>Lorraine B. Ling</i>	Date	November 21, 2001		

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

**CAO, ET AL.**

APPLICATION NO.: **Not Yet Assigned**

Examiner: **Not Yet Assigned**

Group Art Unit: **Not Yet Assigned**

FILING DATE: **November 21, 2001**

TITLE: **ATTENUATED FORMS OF BOVINE  
VIRAL DIARRHEA VIRUS**

Commissioner for Patents  
Washington, D.C. 20231


Sir:

STATEMENT UNDER 37 CFR 1.821

I hereby state that the information recorded in computer readable form is the same as the written sequence listing.

Respectfully submitted,

Date: November 21, 2001

  
Lorraine B. Ling  
Attorney for Applicant(s)  
Reg. No. 35,251

Pfizer Inc  
Patent Department  
150 East 42nd Street – 150/5/49  
New York, NY 10017-5612  
(212) 573-2030

**EXPRESS MAIL NO.: EL 768261649 US**